Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT04347434

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Penza State University (from the registry)
Registry
  • NCT NCT04347434
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04347434. Non-randomized; no masking; primary purpose treatment. Start 2020-02-12 (actual); primary completion 2027-11-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI
Acronym
CONTRAST-2
Condition
Myocardial Infarction, Acute
Condition
Myocardial Strain
Condition
Arterial Stiffness
Condition
Quality of Life
Intervention (Drug)
Atorvastatin 80mg
Lead sponsor
Penza State University (class: other)

Record details

Record id
cardio:ct-nct04347434
Content hash
9de9c035e15a18d32888d3361725099b3454fed5aa3d4f32ccbd4b45784d9d01